Related Experiment Video

Updated: May 5, 2026

Polymalic Acid-based Nano Biopolymers for Targeting of Multiple Tumor Markers: An Opportunity for Personalized Medicine?
14:20

Polymalic Acid-based Nano Biopolymers for Targeting of Multiple Tumor Markers: An Opportunity for Personalized Medicine?

Published on: June 13, 2014

17.8K

Advances and future directions in the targeting of HER2-positive breast cancer: implications for the future

Ishwaria M Subbiah1, Ana Maria Gonzalez-Angulo

  • 1Division of Cancer Medicine, The University of Texas MD Anderson Cancer Center, Houston, TX, 77030-4009, USA.

Current Treatment Options in Oncology
|December 11, 2013
PubMed
Abstract

Insights

HER2-positive breast cancer is now treatable due to new therapies, but drug resistance is a growing challenge. Correctly using these anti-HER2 drugs and participating in clinical trials are key to overcoming resistance.

Area of Science:

  • Oncology
  • Pharmacology
  • Genetics

Background:

  • HER2-positive breast cancer was historically aggressive.
  • Recent advancements have transformed its prognosis.
  • Emergence of drug resistance poses a significant clinical challenge.

Purpose of the Study:

  • To review the evolving landscape of HER2-positive breast cancer treatment.
  • To highlight the challenge of therapeutic resistance.
  • To emphasize the importance of appropriate drug utilization and clinical trial participation.

Main Methods:

  • Review of clinical data and research findings.
  • Analysis of drug efficacy and resistance patterns.
  • Discussion of current therapeutic strategies for HER2-positive breast cancer.

Main Results:

  • Significant improvements in cure rates for HER2-positive breast cancer.
  • Development of effective anti-HER2 therapies.
  • Identification of emerging resistance mechanisms to anti-HER2 drugs.

Conclusions:

  • HER2-positive breast cancer management requires careful consideration of drug indications.
  • Ongoing research and clinical trials are crucial for developing next-generation therapies.
  • Optimizing the use of existing and novel anti-HER2 agents is essential for improving patient outcomes.

More Related Videos

Quantifying Antibody-Dependent Cellular Cytotoxicity in a Tumor Spheroid Model: Application for Drug Discovery13:19

Quantifying Antibody-Dependent Cellular Cytotoxicity in a Tumor Spheroid Model: Application for Drug Discovery

Published on: April 26, 2024

4.2K
Analyzing Tumor and Tissue Distribution of Target Antigen Specific Therapeutic Antibody07:36

Analyzing Tumor and Tissue Distribution of Target Antigen Specific Therapeutic Antibody

Published on: May 16, 2020

4.9K

Related Concept Videos

Targeted Cancer Therapies02:57

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...
7.0K
Targeted Cancer Therapies02:57

Targeted Cancer Therapies

1.4K
Mitogens and the Cell Cycle02:38

Mitogens and the Cell Cycle

Mitogens and their receptors play a crucial role in controlling the progression of the cell cycle. However, the loss of mitogenic control over cell division leads to tumor formation. Therefore, mitogens and mitogen receptors play an important role in cancer research. For instance, the epidermal growth factor (EGF) - a type of mitogen and its transmembrane receptor (EGFR), decides the fate of the cell's proliferation. When EGF binds to EGFR, a member of the ErbB family of tyrosine kinase...
6.3K
Pharmacogenetics of Drug Targets: β₂-Adrenergic Receptors, Apo E, Thymidylate Synthase01:11

Pharmacogenetics of Drug Targets: β₂-Adrenergic Receptors, Apo E, Thymidylate Synthase

Genetic polymorphisms in drug targets have emerged as critical determinants of interindividual variability in drug response and toxicity. Pharmacogenomic investigations increasingly focus on identifying these variations to personalize and optimize therapeutic interventions. A drug target may be a receptor, enzyme, or signaling protein involved in pharmacologic responses or disease-related pathways. While early pharmacogenetic studies focused primarily on drug metabolism, current research...
81
Cancer Vaccines01:30

Cancer Vaccines

Cancer treatment vaccines are a rapidly evolving field that offers a promising approach to immunotherapy. Unlike traditional vaccines that prevent diseases, cancer treatment vaccines are designed to treat existing cancers by stimulating the immune system to recognize and attack cancer cells.
Cancer vaccines come in two categories: preventive (prophylactic) and treatment (active). Preventive vaccines, such as the Human Papillomavirus (HPV) vaccine, protect against viruses that cause certain...
1.3K